Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.

FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. FORMA’s approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms. FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a company headquartered in Cambridge, MA. The firm develops novel cancer therapeutics. Patricia S. Andrews is the current CEO of the firm.\nThe company says this about itself: Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. SDP Oncology's robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology.

Tolero Pharmaceuticals is a biopharmaceutical company that discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering from chronic inflammatory diseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 which targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has a strategic partnership with MannKind Corporation. The company was founded in 2011 and is based in Salt Lake City, Utah.

Sumitomo Pharma Oncology is a novel cancer therapeutics developer. Their research includes survival mechanisms and novel protein interactions. They are committed to pursuing a diverse and purposeful pipeline that investigates drivers of treatment resistance and tumor progression.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Nanjing Novizan Medical Technology Co., Ltd., established on 2016-02-23, Business scope includes licensed projects:Production of Class III Medical Devices;Production of Class II Medical Devices;Class III medical device business;medical service;Internet Information Service for Medical Devices;Drug internet information service;Internet information service;Production of disinfection products for the prevention and control of infectious diseases;Veterinary drug production;Veterinary drug business;Animal Clinic;Inspection and testing service;pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Internet hospital services relying on physical hospitals(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;software development;Manufacturing of computer software, hardware and peripheral equipment;software sales;Veterinary special equipment sales;Retailing of computer software, hardware and auxiliary equipment;Import and export;Technology Import and Export;Import and export agency;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technical extension services;Technology promotion and application services;Experimental analysis instrument sales;Network Equipment Sales;Information system operation and maintenance services;Development of Human Gene Diagnosis and Therapy Technology;internet data service;internet sales(Except for products that require a license for sale);Information system integration service;Network and Information Security Software Development;Health Consulting Services(Does not include medical services);Network technology service;Specialty Chemicals Sales(Free of Hazardous Chemicals);Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Artificial intelligence application software development;Remote Health Management Services;Instrument Manufacturing;Manufacturing of experimental analysis instruments;Manufacturing of Drug Testing Instruments;Instrument sales;Drug testing equipment sales;sales agent;Domestic trade agent;Manufacturing of wearable smart devices;Wearable smart device sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel.

Applied Proteomics is a platform for discovering protein biomarkers that advances proteomics. It offers the application of proteomics in diagnostics and personalized medicine to improve healthcare outcomes. It develops a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

Part of The Mcclay Foundation, Almac Diagnostic Services Ltd. is a company headquartered in Craigavon, UK. The firm engages in development of cancer diagnostics.\nThe company says this about itself: Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. The company, based in Craigavon, UK and Durham, USA has been in existence for over 15 years. Our diagnostic experience spans: Oncology, Immunology, CNS and Infective diseases.

The Rural Development Administration (Korean: 농촌진흥청; Hanja: 農村振興廳, RDA) is one of an agriculture organizations in South Korea and is run under the Ministry of Agriculture, Food and Rural Affairs. The headquarters are in Wansan-gu, Jeonju.

Zhejiang Jukang Biological Engineering Co., Ltd., established on 2015-03-12, Business scope includes general items:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Development of Human Gene Diagnosis and Therapy Technology;Human stem cell technology development and application;Engineering and Technology Research and Experimental Development;Medical equipment rental;Computer and communication equipment rental;Experimental analysis instrument sales;Auto New Car Sales;Manufacturing of experimental analysis instruments;Specialty Chemicals Sales(Free of Hazardous Chemicals);Biochemical product technology research and development;software development;Disinfectant sales(Free of Hazardous Chemicals);Health Consulting Services(Does not include medical services);Wholesale of computer software, hardware and auxiliary equipment;Retailing of computer software, hardware and auxiliary equipment;software sales;Computer System Services;Artificial intelligence application software development;Information Technology Consulting Services;Information system operation and maintenance services;Medical Research and Experimental Development;R&D and application of cell technology;Non-residential real estate leases;housing lease;Special Equipment Sales;Household Appliances Retail;Sales of electrical machinery and equipment;Sales of hygiene products and single-use medical products;Glassware Sales;internet data service;Remote Health Management Services;Information Consulting Service(Not including licensing information consulting services);Business Management Consulting;Home Appliance Sales;Sales of daily chemical products;electronics sales;Conference and Exhibition Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class II Medical Devices;Class III medical device business;Production of Class III Medical Devices;Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Guangdong General Hospital (Chinese: 广东省人民医院 meaning "Guangdong Provincial People's Hospital") is a large hospital, founded in 1946, located in Yuexiu District, Guangzhou, Guangdong, China.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Shanghai Bomei Biotechnology Co., Ltd., established on 2011-12-30, The scope of business includes engaging in technology development in the field of biotechnology products,technical consulting,Technology Transfer and Technical Services;equipment,Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Computer software and auxiliary equipment sales(Products other than computer security information). [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.